ArticleBlood advances2026

Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Jan-Michel Heger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.